Article
Towards a turning point of neuroblastoma therapy.
Cancer letters - 30 Dec 2012
Tonini Gian Paolo, Nakagawara Akira, Berthold Frank
Abstract excerpt
In 1983, the MYCN oncogene amplification was discovered in neuroblastoma cells and few years later its prognostic role was clearly demonstrated. The first European study, in which MYCN gene status is taken as prognostic factor for therapeutic decision, was released by SIOPEN and GPOH in 1995. Afterward, other trials were released by SIOPEN, GPOH, COG, and JNBSG in which MYCN gene amplification was employed as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.